MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ahj.2025.09.013

Медицинская библиотека · American heart journal · 2025

Vericiguat and hypotension in patients with heart failure and reduced ejection fraction: VERIFY-HF registry.

Matsumoto Shingo, Nasu Takahito, Fujimoto Wataru, Kagiyama Nobuyuki, Shiraishi Yasuyuki, Ishii Shunsuke, Ijichi Takeshi, Nakazawa Gaku, Ikeda Takanori, Kanaoka Koshiro, VERIFY-HF investigators

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Real-world characteristics and outcomes in patients with heart failure (HF) and reduced ejection fraction (HFrEF) treated with vericiguat remain unclear. We investigated patient characteristics, hypotension-the most relevant clinical event-, and outcomes after initiating vericiguat in patients with HFrEF.

METHODS

In this nationwide, multicentre retrospective study involving 22 hospitals in Japan, we examined symptomatic or asymptomatic hypotension and drug discontinuation within 90 days after initiation of vericiguat in patients with left ventricular ejection fraction <45%. The association between hypotension and HF outcomes was also examined.

RESULTS

Among the 799 patients with HFrEF, the mean age was 69.6 years, and 218 (27.3%) were female. Of them, 316 (39.5%) had New York Heart Association classification III or IV, and 329 (41.8%) had systolic blood pressure (sBP) <100 mm Hg. Hypotension was observed in 25.3% of patients within 90 days, with asymptomatic hypotension being the most common (17.9%). By contrast, drug discontinuation related to hypotension was less frequent (4.4%). After adjustment, sBP <100 mm Hg, low body mass index, and in-hospital vericiguat initiation were associated with the incidence of hypotension within 90 days. Patients who experienced hypotension had a greater risk of cardiovascular death or HF hospitalization than those who did not (P = .01).

CONCLUSIONS

Although hypotension was relatively common soon after starting vericiguat, they were not often associated with drug discontinuation. Patients experiencing hypotension had a greater risk of HF outcomes, but this would be primarily associated with their vulnerability, given the infrequent discontinuation.

Для цитирования: Matsumoto Shingo, Nasu Takahito, Fujimoto Wataru, Kagiyama Nobuyuki, Shiraishi Yasuyuki, Ishii Shunsuke, Ijichi Takeshi, Nakazawa Gaku, Ikeda Takanori, Kanaoka Koshiro, VERIFY-HF investigators. Vericiguat and hypotension in patients with heart failure and reduced ejection fraction: VERIFY-HF registry.. American heart journal. 2025. DOI: 10.1016/j.ahj.2025.09.013.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.